HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
-
REGULATORY MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
-
REGULATORY MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
-
REGULATORY AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
-
ORGANIZATION Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
May 29, 2015
-
REGULATORY MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
-
ORGANIZATION FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
May 28, 2015
-
REGULATORY MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
-
BUSINESS Astellas’s New 3-Year Plan Targets Sales Growth in Mid-Single-Digit Range
May 27, 2015
-
REGULATORY ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
-
BUSINESS Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement
May 26, 2015
-
BUSINESS Sales Increase 19.3% for 3 Generic-Only Makers; Incentive for DPC Hospitals Spurs Growth
May 25, 2015
-
TRENDS Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
BUSINESS Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit
May 21, 2015
-
REGULATORY Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
-
BUSINESS Top 4 Drug Wholesalers Report 0.82% Operating Profit Rate in FY2014
May 20, 2015
-
BUSINESS Biogen Japan Sets to Quadruple Sales in 2 Years: New Chief
May 19, 2015
-
REGULATORY Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
-
BUSINESS Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
-
REGULATORY PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…